BRPI0813583A2 - Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo - Google Patents

Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo

Info

Publication number
BRPI0813583A2
BRPI0813583A2 BRPI0813583-5A2A BRPI0813583A BRPI0813583A2 BR PI0813583 A2 BRPI0813583 A2 BR PI0813583A2 BR PI0813583 A BRPI0813583 A BR PI0813583A BR PI0813583 A2 BRPI0813583 A2 BR PI0813583A2
Authority
BR
Brazil
Prior art keywords
response
anticanus
prognosing
patient
identifying
Prior art date
Application number
BRPI0813583-5A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Sharat Singh
Jeanne Harvey
Original Assignee
Prometheus Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Lab Inc filed Critical Prometheus Lab Inc
Publication of BRPI0813583A2 publication Critical patent/BRPI0813583A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0813583-5A2A 2007-07-13 2008-07-11 Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo BRPI0813583A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94982007P 2007-07-13 2007-07-13
PCT/US2008/069764 WO2009012140A2 (en) 2007-07-13 2008-07-11 Drug selection for lung cancer therapy using antibody-based arrays

Publications (1)

Publication Number Publication Date
BRPI0813583A2 true BRPI0813583A2 (pt) 2014-12-30

Family

ID=40260313

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813583-5A2A BRPI0813583A2 (pt) 2007-07-13 2008-07-11 Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo

Country Status (15)

Country Link
US (1) US9250243B2 (enExample)
EP (1) EP2179291B1 (enExample)
JP (1) JP5352585B2 (enExample)
KR (1) KR101553723B1 (enExample)
CN (1) CN101802618B (enExample)
AU (1) AU2008276251B2 (enExample)
BR (1) BRPI0813583A2 (enExample)
CA (1) CA2693013A1 (enExample)
ES (1) ES2526211T3 (enExample)
IL (1) IL203201A (enExample)
MX (1) MX2010000405A (enExample)
NZ (1) NZ582618A (enExample)
RU (2) RU2519647C2 (enExample)
WO (1) WO2009012140A2 (enExample)
ZA (1) ZA201000310B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
NZ582618A (en) 2007-07-13 2012-07-27 Prometheus Lab Inc Drug selection for lung cancer therapy using antibody-based arrays
US20110166154A1 (en) * 2008-01-25 2011-07-07 Bristol-Myers Squibb Company Identification of predictive markers of response to dasatinib in human colon cancer
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2239579A1 (en) 2009-04-10 2010-10-13 PamGene B.V. Method for the predicting of the response of non-small cell lung cancer patients to targeted pharmacotherapy
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
DK2491385T3 (en) 2009-10-20 2017-08-28 Diatech Holdings Inc PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS
US8679812B2 (en) 2009-12-28 2014-03-25 Kikkoman Corporation Method for extracting Staphylococcus aureus antigen, reagent for extracting Staphylococcus aureus antigen, and method for assessing Staphylococcus aureus
US8883985B2 (en) 2010-02-16 2014-11-11 National University Corporation Kyoto Institute Of Technology Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier
US8574922B2 (en) * 2010-03-08 2013-11-05 Bin Hong Targeted cell separation and enumeration device and the use thereof
US20110318336A1 (en) * 2010-03-29 2011-12-29 George Mason Intellectual Properties, Inc. Identification and Treatment of Aggressive Lung Cancer Tumors
US20110301859A1 (en) * 2010-06-04 2011-12-08 N-Of-One Therapeutics, Inc. Personalized molecular medicine
WO2011158863A1 (ja) * 2010-06-16 2011-12-22 国立大学法人九州大学 タンパク質キナーゼの新規基質ペプチド
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
AU2011305445B2 (en) 2010-09-24 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
SG191230A1 (en) 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
JP6323978B2 (ja) 2010-12-24 2018-05-16 アークレイ株式会社 癌細胞の検出方法
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
BR112013020992A2 (pt) 2011-02-17 2016-10-11 Nestec Sa aparelho e método para isolamento de leucócitos e células tumorosas por meio de filtração
MX343327B (es) 2011-02-17 2016-11-01 Nestec Sa Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
EP2681552A2 (en) 2011-03-02 2014-01-08 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
KR20140020318A (ko) 2011-04-04 2014-02-18 네스텍 소시에테아노님 위암 환자의 생존률 예측 및 개선 방법
WO2012138694A2 (en) * 2011-04-07 2012-10-11 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
WO2013006810A1 (en) 2011-07-06 2013-01-10 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
KR101851425B1 (ko) * 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
CN102998439A (zh) * 2011-09-14 2013-03-27 佳木斯大学 同时检测葡萄糖、尿酸、甘油三酯及胆固醇的微流控纸芯片及制造方法
EP2788752B1 (en) * 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer
EP2605014A1 (en) * 2011-12-16 2013-06-19 Merck Patent GmbH General strategy for antibody library screening
ES2678211T3 (es) 2012-03-27 2018-08-09 Ventana Medical Systems, Inc. Conjugados de señalización y procedimientos de uso
EP2852840B1 (en) * 2012-05-23 2019-10-09 F.Hoffmann-La Roche Ag Selection method for therapeutic agents
CN102841201B (zh) * 2012-08-31 2015-06-03 马鞍山微因泰克生物科技有限公司 一种以肺癌为主的早期癌症联合普查蛋白芯片
ES2638971T3 (es) 2012-10-05 2017-10-24 Nestec S.A. Métodos para predecir y monitorizar la cicatrización de la mucosa
WO2014067642A1 (en) * 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2954328A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
HK1218939A1 (zh) 2013-02-05 2017-03-17 Nestec S.A. 用於非小细胞肺癌疗法的药物选择
CA2900842C (en) 2013-03-12 2020-01-21 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
EP3373010A1 (en) 2013-05-21 2018-09-12 Pierian Holdings, Inc. Method for selecting a therapy for the treatment of colorectal cancer patients
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
RU2571821C2 (ru) * 2013-09-26 2015-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Способ выявления циркулирующих опухолевых клеток, микроэмбол и апоптотических телец в крови больных раком легкого человека
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR101527797B1 (ko) 2014-06-03 2015-06-15 한국과학기술원 신호전달경로의 활성화 상태 분석방법 및 이를 이용한 개인 맞춤형 치료제의 선정방법
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
RU2017122720A (ru) 2014-12-05 2019-01-10 Нестек С.А. Непрямые однородные анализы по изменению подвижности для детекции биологических препаратов в образцах пациента
WO2016112272A1 (en) * 2015-01-09 2016-07-14 Metastat, Inc. Method of use for inhibitors of epidermal growth factor receptor variant iii
CN106854246B (zh) * 2015-12-09 2020-05-22 南京英瀚斯生物科技有限公司 一种针对pi3k的纳米抗体及其临床应用
RU2616533C1 (ru) * 2016-03-15 2017-04-17 Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) Способ прогнозирования эффективности терапии эверолимусом у больных метастатическим раком почки
CN106093394B (zh) * 2016-06-07 2017-12-26 中国人民解放军第二军医大学 Flt3蛋白在制备肝癌对索拉菲尼疗效评估试剂盒中的应用
US10761081B2 (en) * 2016-06-12 2020-09-01 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
KR20200009095A (ko) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. 크론병 환자에서 점막 치유를 평가하는 방법
CA3066507A1 (fr) * 2017-06-08 2018-12-13 Carcidiag Biotechnologies Methode d'isolement et de detection de cellules souches cancereuses
KR101897250B1 (ko) * 2017-07-11 2018-09-10 광주과학기술원 항암제 조합에 대한 단일 세포 분석 칩
AU2018315434A1 (en) 2017-08-10 2020-04-02 The Institute Of Cancer Research: Royal Cancer Hospital Materials and methods for stratifying and treating cancers
WO2019200326A1 (en) 2018-04-13 2019-10-17 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
CN110031626A (zh) * 2019-04-02 2019-07-19 浙江理工大学 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11413289B2 (en) 2019-05-16 2022-08-16 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
WO2022155311A1 (en) * 2021-01-14 2022-07-21 The Regents Of The University Of California Methods and systems for analysis of drug target engagement and treatment of cancer
US20250003959A1 (en) * 2021-07-07 2025-01-02 Institute For Systems Biology Cell analysis methods, compositions, and uses
WO2023058624A1 (ja) * 2021-10-08 2023-04-13 コニカミノルタ株式会社 染色方法、評価方法および標本

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US5516931A (en) * 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4975532A (en) * 1986-11-28 1990-12-04 Sclavo, Inc. Method to derivatize dextran
JPH01163661A (ja) 1987-10-02 1989-06-27 E I Du Pont De Nemours & Co ＩｇＧ捕捉抗体および多重単クローン性抗体検出系を用いたイムノアツセイ
US5089419A (en) * 1989-08-07 1992-02-18 International Canine Genetics Detection of pregnancy by identification of the c peptide of relaxin in the urine of animals
US5120660A (en) * 1989-12-05 1992-06-09 International Canine Genetics, Inc. Method for canine fertility detection
FR2672128B1 (fr) * 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
US6251581B1 (en) * 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5332662A (en) * 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
JPH06109734A (ja) 1992-09-30 1994-04-22 S R L:Kk 抗原の測定方法
US6201109B1 (en) * 1993-01-13 2001-03-13 Dade Behring Marburg Gmbh Assay for bone alkaline phosphatase
JP3825815B2 (ja) 1994-01-31 2006-09-27 信義 清水 上皮細胞増殖因子レセプターに対するモノクローナル抗体の結合体ならびにその複合体およびその細胞への嵌入方法
FI98961C (fi) 1994-08-26 1997-09-10 Medix Biochemica Ab Oy Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi
US5876944A (en) * 1996-06-10 1999-03-02 Bayer Corporation Method for amplification of the response signal in a sandwich immunoassay
US6780596B2 (en) * 1998-09-17 2004-08-24 Ashni Naturaceuticals, Inc. Methods for determining the activity of complex mixtures
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
RU2165081C2 (ru) 1999-01-05 2001-04-10 Ставропольский научно-исследовательский противочумный институт Способ индикации микроорганизмов
US6335173B1 (en) * 1999-01-12 2002-01-01 Verve, Ltd. C/O James Bell Methods for detecting an analyte of interest using tyramide coating technology
GB9901072D0 (en) 1999-01-19 1999-03-10 Imp Cancer Res Tech Methods for detecting changes to a macromolecular component of a cell
US6972198B2 (en) * 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
RU2149404C1 (ru) * 1999-03-24 2000-05-20 Московский НИИ глазных болезней им. Гельмгольца Способ прогнозирования клинического течения увеальной меланомы
US6322980B1 (en) * 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6649351B2 (en) * 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
DE19926010C2 (de) * 1999-06-08 2003-01-30 Bundesdruckerei Gmbh Wert- und Sicherheitsdokument mit Sicherheitsmerkmal mit Piezo-Effekt-basierten Eigenschaften und dazugehöriges Nachweisverfahren
US7033781B1 (en) * 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
AU1630501A (en) * 1999-10-08 2001-04-23 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
CA2385614A1 (en) * 1999-10-13 2001-04-19 Timothy Johann Multiplex cytokine analysis
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US6511809B2 (en) * 2000-06-13 2003-01-28 E. I. Du Pont De Nemours And Company Method for the detection of an analyte by means of a nucleic acid reporter
US7785810B2 (en) 2000-09-09 2010-08-31 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
US6797481B1 (en) * 2000-10-17 2004-09-28 Dade Behring Marburg Gmbh Simultaneous screening of multiple analytes
US7635571B2 (en) * 2000-12-07 2009-12-22 Siemens Healthcare Diagnostics Products Gmbh Amplified signal in binding assays
DE10064827A1 (de) 2000-12-22 2002-06-27 Dade Behring Marburg Gmbh Nachweisverfahren
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20020168641A1 (en) * 2001-03-09 2002-11-14 Bruce Mortensen Fluorescein-cyanine 5 as a fluorescence resonance energy transfer pair
US20020142361A1 (en) * 2001-03-27 2002-10-03 Emmert-Buck Michael R. Biodetection method
US20040265923A1 (en) * 2001-05-03 2004-12-30 James Gilmore Method and apparatus to determine the performance of protein arrays
WO2002103321A2 (en) * 2001-06-14 2002-12-27 Anadys Pharmaceuticals, Inc. Methods of screening for ligands of target molecules
US7695926B2 (en) * 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
AU2002322461B2 (en) 2001-07-12 2007-12-06 Vegenics Limited Lymphatic endothelial cells materials and methods
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US8323903B2 (en) * 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
US20050069962A1 (en) * 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
AU2002363530A1 (en) * 2001-11-07 2003-05-19 Sensor Technologies Llc Method of identifying energy transfer sensors for analytes
EP1478765A4 (en) * 2002-03-05 2006-12-06 Aclara Biosciences Inc MULTIPLEX ANALYSIS USING MEMBRANE-FIXED SENSITIZERS
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
AU2003223495A1 (en) 2002-04-05 2003-10-27 Cell Signaling Technology, Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
FR2843126B1 (fr) * 2002-08-01 2006-01-27 Cis Bio Int "methode de determination d'une activite enzymatique endoglycosidase"
US20040235002A1 (en) * 2002-09-20 2004-11-25 Sangamo Biosciences, Inc. Multiplex screening assays
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
AU2003291736A1 (en) * 2002-11-05 2004-06-03 Cell Signaling Technology, Inc. Methods and materials for examining pathways associated with glioblastoma progression
US20030153013A1 (en) * 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
WO2004071572A2 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
JP3857677B2 (ja) * 2003-02-18 2006-12-13 和久 蓮井 免疫組織化学的染色による抗原の検出方法
BRPI0408928A (pt) * 2003-04-01 2006-09-12 Monogram Biosciences Inc métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
JPWO2004099407A1 (ja) * 2003-05-09 2006-07-13 株式会社生物有機化学研究所 抗癌剤感受性試験方法
JP2006340602A (ja) * 2003-06-13 2006-12-21 Orient Cancer Therary:Kk モデルマウス
US20040265938A1 (en) 2003-06-25 2004-12-30 Jose Remacle Method for the determination of cell activation
WO2005013804A2 (en) * 2003-08-05 2005-02-17 Euro-Celtique S.A. ErbB RECEPTOR METHODS AND KITS FOR MONITORING CHEMOTHERAPY RESISTANCE
US7279286B2 (en) * 2003-09-11 2007-10-09 Sanofi-Aventis Deutschland Gmbh High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity
FI20031370A0 (fi) 2003-09-23 2003-09-23 Wallac Oy Automaattinen hemoglobiinin määritysmenetelmä vastasyntyneiden seulontaan
WO2005037071A2 (en) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
ES2343840T3 (es) 2003-11-04 2010-08-11 Bayer Healthcare Llc Procedimientos inmunohistoquimicos para supervisar los niveles de perk.
JP2007526460A (ja) 2004-03-03 2007-09-13 バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞集団のタンパク質発現プロファイルの作成のための分析用プラットフォームおよび方法
US20060024722A1 (en) * 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
WO2006031815A2 (en) * 2004-09-13 2006-03-23 Monogram Biosciences, Inc. Methods and compositions for proximity assays
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
WO2006045991A1 (en) 2004-10-25 2006-05-04 Astrazeneca Ab Method to predict whether a tumor will react to a chemotherapeutic treatment
WO2006055739A2 (en) 2004-11-17 2006-05-26 Robert Sack Stationary phase antibody arrays for trace protein analysis
WO2006054991A1 (en) 2004-11-17 2006-05-26 Immunivest Corporation Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
DE102004056794B4 (de) 2004-11-24 2010-08-26 Protagen Ag Verwendung einer Anordnung und Verfahren zur Validierung von Bindern
JPWO2006082866A1 (ja) * 2005-02-01 2008-06-26 萬有製薬株式会社 ｐ５３の機能異常の検出方法、癌の分子診断方法及び癌治療に有効な化合物の評価方法
WO2006101925A2 (en) * 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
US8367351B2 (en) 2006-05-05 2013-02-05 Historx, Inc. Methods for determining signal transduction activity in tumors
WO2008019375A2 (en) 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Proteomic patterns of cancer prognostic and predictive signatures
CN104198705B (zh) * 2006-09-21 2017-06-09 雀巢产品技术援助有限公司 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列
BRPI0717416A2 (pt) * 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
BRPI0718413A2 (pt) 2006-10-23 2014-03-11 The Uab Research Foundation Métodos para prever a sensibilidade de uma célula concerosa a um primeiro agente anticâncer, para prever ou monitorar a eficácia de um agente anticâncer, e para determinar uma dose eficaz para um agente anticâncer, kit de detecção, e, sistema de ensaio multiplex
WO2008055314A1 (en) * 2006-11-10 2008-05-15 Dimerix Bioscience Pty Ltd Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
WO2008064884A1 (en) 2006-11-28 2008-06-05 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
JP2008292424A (ja) 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
NZ582618A (en) 2007-07-13 2012-07-27 Prometheus Lab Inc Drug selection for lung cancer therapy using antibody-based arrays
EP2065475A1 (en) 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
US20120270745A1 (en) * 2009-07-15 2012-10-25 Prometheus Laboratories Inc. Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples
JP5795311B2 (ja) * 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
US20120231965A1 (en) * 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
US9719995B2 (en) * 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling

Also Published As

Publication number Publication date
ES2526211T3 (es) 2015-01-08
CN101802618B (zh) 2015-02-25
CA2693013A1 (en) 2009-01-22
AU2008276251A1 (en) 2009-01-22
AU2008276251B2 (en) 2014-04-24
WO2009012140A2 (en) 2009-01-22
WO2009012140A3 (en) 2009-03-05
US20110275097A9 (en) 2011-11-10
IL203201A (en) 2015-08-31
EP2179291B1 (en) 2014-10-22
EP2179291A4 (en) 2010-07-07
JP2010533842A (ja) 2010-10-28
CN101802618A (zh) 2010-08-11
RU2010105037A (ru) 2011-08-20
NZ582618A (en) 2012-07-27
US9250243B2 (en) 2016-02-02
KR101553723B1 (ko) 2015-09-16
RU2013142450A (ru) 2015-03-27
ZA201000310B (en) 2011-04-28
RU2519647C2 (ru) 2014-06-20
JP5352585B2 (ja) 2013-11-27
MX2010000405A (es) 2010-03-04
US20090035792A1 (en) 2009-02-05
EP2179291A2 (en) 2010-04-28
KR20100063011A (ko) 2010-06-10

Similar Documents

Publication Publication Date Title
CY2016040I2 (el) Επιλογες θεραπειας για τη νοσο του fabry
EP2213321A4 (en) AEROSOL INHALATION SYSTEM
BRPI0816524A2 (pt) "sistema de moldagem de tecido macio, método para moldagem de um tecido macio de um paciente e material laminado"
EP2147437A4 (en) SEEDING REPLICATION
BRPI0810646A2 (pt) " compostos farmacêuticos ".
HUE041446T2 (hu) Új immunterápia számos tumor ellen, köztük neuronális és agytumor ellen
BRPI0821087A2 (pt) Preparação externa para a pele.
BRPI0807896A2 (pt) Fórceps bipolares não-aderentes.
BRPI0819714A2 (pt) Formulações de proteína e métodos de produção das mesmas.
BRPI0722082A2 (pt) Ligantes para imagiologia da inervação cardíaca
PL2535716T3 (pl) Marker nowotworowy i cel terapeutyczny
EP2213220A4 (en) ENDOSCOPE SYSTEM
EP2167083A4 (en) NOVEL HETEROARYL-3-AZABICYCLOÝ3.1.0HEXANES, THEIR METHODS OF PREPARATION AND THEIR USE AS MEDICAMENTS
BRPI0810948A2 (pt) "composição hidratante, usos da composição e método para hidratar ou umidificar a pele"
BRPI0719383A2 (pt) Formulações de inalação de bisfosfonato ligado a polímero e métodos para a utilização das mesmas
IL202359A0 (en) 17??-cyano-19-nor-androst-4-ene derivative, use thereof and medicaments containing said derivative
ZA201005306B (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
EP2092884A4 (en) MEDICAL IMAGING MARKER
IL202325A0 (en) 17??-cyano-19-androst-4-ene derivative, use thereof and medicaments containing said derivative
ZA201000582B (en) 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives,preparation and therapeutic use thereof
FI20070595A0 (fi) Menetelmä ja järjestelmä käyttäjän identiteetin hallintaan
EP2150309A4 (en) MEDICAL IMPLANTABLE CABLE WITH SWIVEL SEGMENTS
PL383737A1 (pl) Sposób odtworzenia informacji genetycznej zwierzęcia, zwłaszcza tura
UA16404S (uk) Туфлі жіночі
UA17802S (uk) Етикетка для медичних препаратів

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NESTEC S.A. (CH)

B15K Others concerning applications: alteration of classification

Ipc: G01N 33/574 (2006.01), G01N 33/50 (2006.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2500 DE 04/12/2018 POR TER SIDO INDEVIDA.

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL